Sign in

PALI on Nasdaq

PALISADE BIO, INC.

In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.”3 It is headquartered in Carlsbad, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with CytRx, Artiva Biotherapeutics, Inc. or Inhibikase Therapeutics, Inc., or pick any stock.

  • TickerPALI on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersCarlsbad, California1
  • Incorporated inDE2
  • Business address7750 El Camino Real, Suite 5200, Carlsbad, Ca 920092
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Crohn’s disease (“CD”).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-13.0%Return on equity4

Financial statements

Revenue5674$0 in 2025
0$100.0K$200.0K$300.0K2019: $15.4K$15.4K20192020: $13.5K$13.5K2020−12%2022: $0$020222023: $250.0K$250.0K20232024: $0$020242025: $0$02025
Operating income589674-$18.1M in 2025+109% since 2019
-$60.0M-$40.0M-$20.0M02019: -$8.6M-$8.6M20192020: -$9.3M-$9.3M2020+8%2021: -$41.9M-$41.9M2021+350%2022: -$15.7M-$15.7M2022−62%2023: -$13.1M-$13.1M2023−17%2024: -$14.9M-$14.9M2024+14%2025: -$18.1M-$18.1M2025+22%
Net income589674-$16.8M in 2025+101% since 2019
-$30.0M-$20.0M-$10.0M02019: -$8.4M-$8.4M20192020: -$10.3M-$10.3M2020+24%2021: -$26.6M-$26.6M2021+158%2022: -$14.3M-$14.3M2022−46%2023: -$12.3M-$12.3M2023−14%2024: -$14.4M-$14.4M2024+17%2025: -$16.8M-$16.8M2025+16%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Research and development$10.2M$9.1M
General and administrative$7.9M$5.8M
Total operating expenses$18.1M$14.9M
Loss from operations-$18.1M-$14.9M
Interest expense-$10.0K-$12.0K
Other income, net$1.3M$433.0K
Total other income, net$1.3M$421.0K
Net loss-$16.8M-$14.4M
Basic weighted average shares used in computing net loss per common share55.7M shares1.4M shares
Diluted weighted average shares used in computing net loss per common share55.7M shares1.4M shares
Basic net loss per common share-$0.30-$10.19
Diluted net loss per common share-$0.30-$10.19

Compare PALISADE BIO, INC. with another company

Corporate structure

PALISADE BIO, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PALISADE BIO, INC.

  • PALISADE BIO, INC. Carlsbad, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PALISADE BIO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$04 Dec 31, 2025$3.0K4 Dec 31, 2024−100.0%
Operating-lease assets (leased space)$04 Dec 31, 2025$84.0K4 Dec 31, 2024−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$133.4M4 Dec 31, 2025$9.8M4 Dec 31, 2024+1258.2%

Leadership

Who has led PALISADE BIO, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard Garr2007–2016
  2. Thomas Hallam2021–2022
  3. Mitchell Lawrence Jones2024

Chair

  1. Karl Johe2007–2008
  2. Kenneth C. Carter2019

President

  1. Richard Garr2007–2008

Chief financial officer

  1. Richard Garr2007
  2. John Conron2007–2011
  3. Jones Jonathan Brian Lloyd2015–2017
  4. Mitchell Lawrence Jones2024
2010201520202025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorJ.D. Finley named Jan 19, 2023 to May 10, 202438
  • Executive OfficerHerbert Slade named Apr 10, 202339
  • Executive OfficerRobert McRae named Apr 10, 202339
  • Executive OfficerJD Finley named May 20, 202240
  • DirectorDonald Williams named May 20, 2022 to May 10, 202438

Former names

  • Seneca Biopharma, Inc.Jan 28, 2020 to Apr 26, 20212
  • Neuralstem, Inc.Apr 3, 2006 to Jan 23, 20202

Timeline

  1. Aug 10, 20268-K Results of operations41
  2. Jun 11, 20268-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote42
  3. May 12, 20268-K Results of operations43
  4. Apr 2, 20268-K Other events44
  5. Dec 4, 20258-K Bylaws or fiscal year changed; Shareholder vote45
  6. Oct 22, 20258-K Executive or director change46
  7. Oct 20, 20258-K Shareholder vote47
  8. Oct 16, 20258-K Other events48
  9. Oct 9, 20258-K Other events49
  10. Sep 26, 20258-K Other events50
  11. Sep 18, 20258-K Other events51
  12. Sep 5, 20258-K Executive or director change52
  13. May 8, 2024New chief executive Mitchell Lawrence Jones becomes CEO12
  14. Apr 29, 2021New chief executive Thomas Hallam becomes CEO13
  15. Jan 29, 2007New chief executive Richard Garr becomes CEO14

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.38) a share, on Nov 10, 2025.53

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results41
  2. May 12, 2026Reported quarterly or annual results43
  3. Mar 27, 2024Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

403 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 121 insider forms, 42 large holders, 5 private raises, 154 other. The latest 20:

  1. Oct 7, 20264 EDGAR
  2. Oct 7, 20264 EDGAR
  3. Oct 5, 20264 EDGAR
  4. Aug 21, 20264 EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Aug 10, 20268-K EDGAR
  8. Aug 10, 202610-Q EDGAR
  9. Jul 29, 2026SCHEDULE 13G EDGAR
  10. Jul 10, 20264 EDGAR
  11. Jul 8, 20264 EDGAR
  12. Jul 8, 20264 EDGAR
  13. Jul 8, 20264 EDGAR
  14. Jul 7, 2026144 EDGAR
  15. Jul 7, 2026144 EDGAR
  16. Jul 6, 20264 EDGAR
  17. Jun 18, 20264 EDGAR
  18. Jun 18, 20263 EDGAR
  19. Jun 12, 20264 EDGAR
  20. Jun 12, 20264 EDGAR

The 403 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

28 open-market trades by officers, directors and large owners since October 2021: 23 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 9, 2026Baltera Robert Jr.DirectorBuy25,000$1.96$49.0KForm 4
Jul 8, 2026Baltera Robert Jr.DirectorBuy20,000$1.99$39.8KForm 4
Jul 7, 2026Baltera Robert Jr.DirectorBuy30,000$2.03$60.9KForm 4
Jul 7, 2026Jones Mitchell LawrenceChief Medical OfficerSale51,880$2.05$106.4KForm 4
Jul 7, 2026Finley John DavidCEO, CFOSale146,798$2.07$303.9KForm 4
Jul 6, 2026Baltera Robert Jr.DirectorBuy20,000$2.05$41.0KForm 4
Jul 2, 2026Baltera Robert Jr.DirectorBuy10,000$1.98$19.8KForm 4
Jul 1, 2026Baltera Robert Jr.DirectorBuy20,000$1.98$39.6KForm 4
Feb 12, 2026Jones Mitchell LawrenceChief Medical OfficerSale1,989$1.75$3.5KForm 4
Feb 12, 2026Finley John DavidCEO, CFOSale3,896$1.75$6.8KForm 4
Jan 16, 2026Williams Donald AllenDirectorBuy5,000$1.67$8.3KForm 4
Jan 9, 2026Williams Donald AllenDirectorBuy5,000$1.88$9.4KForm 4
May 28, 2024Williams Donald AllenDirectorBuy1,000$4.86$4.9KForm 4
May 24, 2024Finley John DavidCEO, CFOBuy1,000$4.81$4.8KForm 4
Feb 6, 2024Finley John DavidCEO, CFOBuy10,000$0.47$4.7KForm 4
Jan 31, 2024Finley John DavidCEO, CFOBuy10,000$0.56$5.6KForm 4
Jan 31, 2024Williams Donald AllenDirectorBuy10,000$0.61$6.1KForm 4
Sep 27, 2023Williams Donald AllenDirectorBuy20,000$0.54$10.8KForm 4
Sep 27, 2023Finley John DavidCEO, CFOBuy15,000$0.54$8.1KForm 4
Sep 14, 2023Trenschel Robert J.DirectorSale300$0.64$192Form 4

All 28 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025J.D. Finley68$575.0K$18.8M72
2025Mitchell JonesM.D., Ph.D.48$440.0K$15.5M72
2024Chief Executive Officer and Chief Financial Officer$542.0K$813.0K72
2024President and Chief Medical Officer$415.0K$581.0K72

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 6, 2024Raised $4 million in a private offering of equity Form D: 1 investor so far Form D
  2. Feb 1, 2024Raised $2.5 million in a private offering of securities Form D: 15 investors so far Form D
  3. Apr 5, 2023Raised $4 million in a private offering of equity Form D: 9 investors so far Form D
  4. Jan 4, 2023Raised $2.5 million in a private offering of securities Form D: 6 investors so far Form D
  5. May 10, 2022Raised $2.4 million in a private offering of securities Form D: 5 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Soleus Capital Management, L.P.13,063,687$27.3M0.9%New
B Group, Inc.11,414,285$23.9M13.5%No change
Ameriprise Financial Inc11,081,434$23.2M0.0%−428,886
Jupiter Topco LLC10,689,452$22.4M0.0%New
BlackRock, Inc.10,436,760$21.8M0.0%+8,560,420
Octagon Capital Advisors LP10,276,317$21.5M2.0%No change
Perceptive Advisors LLC8,425,065$17.6M0.3%−503,084
Ra Capital Management, L.P.7,124,116$14.9M0.1%No change
Franklin Resources Inc5,785,189$12.1M0.0%No change
Point72 Asset Management, L.P.5,253,403$11.0M0.0%+4,841,631
Boxer Capital Management, LLC4,799,875$10.0M0.8%No change
Adage Capital Partners Gp, L.l.c.4,500,000$9.4M0.0%No change
Eversept Partners, LP4,182,785$8.7M0.5%−804,714
Geode Capital Management, LLC3,760,485$7.9M0.0%+2,214,245
Wellington Management Group Llp3,703,936$7.7M0.0%+799,025
Goldman Sachs Group Inc3,578,020$7.5M0.0%−1,795,931
Federated Hermes, Inc.3,136,607$6.6M0.0%No change
Squadron Capital Management LLC3,000,000$6.3M2.1%No change
Propel Bio Management, LLC2,582,388$5.4M2.8%+1,467,388
Vestal Point Capital, LP2,500,000$5.2M0.1%No change
State Street Corp2,475,648$5.2M0.0%+1,839,451
Morgan Stanley2,474,069$5.2M0.0%−2,077,464
Orbimed Advisors LLC2,333,000$4.9M0.1%No change
Great Point Partners LLC2,284,819$4.8M1.1%−1,120,938
Sphera Funds Management Ltd.2,257,106$4.7M0.7%+523,635

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How PALISADE BIO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPALISADE BIO, INC.1
  • CIK0001357459
  • Employer ID (EIN)52-20072923
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address7750 El Camino Real, Suite 5200, Carlsbad, CA 920091
  • Phone(858) 704-49001
  • Shares outstanding174,270,558 as of Aug 6, 202611
  • Public float$11.2M as of Jun 30, 20253
  • AuditorBaker Tilly US, LLP, New York, NY PCAOB ID 23; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceApr 3, 20061
  • Filings1,272 in all: 8-K (357), 4 (277), 10-Q (56), 424B3 (55), CORRESP (43), UPLOAD (34), EFFECT (33), 3 (30)1
    All 62 form types

    424B5 (27), DEF 14A (25), 425 (22), DEFA14A (22), SC 13G/A (22), S-3 (21), 10-K (18), SC 13G (18), 5 (15), SCHEDULE 13G/A (14), PRE 14A (13), S-1/A (13), 8-K/A (12), D (12), S-3/A (12), SCHEDULE 13G (12), S-8 (11), 4/A (10), S-1 (9), 3/A (6), SB-2/A (6), 10QSB (4), 424B4 (4), ARS (4), FWP (4), SC 13D (4), 10-Q/A (3), 144 (3), 5/A (3), NT 10-Q (3), 10KSB (2), 8-A12B (2), DRS (2), POS AM (2), POS EX (2), RW (2), S-1MEF (2), S-4/A (2), SB-2 (2), SC 13D/A (2), SEC STAFF LETTER (2), 10-K/A (1), 25 (1), 424B2 (1), AW (1), CERTAMX (1), CERTNAS (1), D/A (1), DEFR14A (1), NT 10-K (1), POS462B (1), POS462C (1), REGDEX/A (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Aug 10, 2026

Securities registered for trading

ClassSymbolExchange
common stock, $0.01 par valuePALINasdaq

From the cover page of the 10-K filed Mar 20, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks PALISADE BIO, INC. names in Item 1A of its 10-K filed Mar 20, 2026: 53 risks under these headings, as written.3

  • Risks Related to Our Development, Commercialization and Regulatory Approval of Our Product Candidates
  • Our business depends on the successful clinical development, regulatory approval, and commercialization of our lead asset PALI-2108.
  • There are substantial risks in drug development, and, as a result, we may not be able to successfully develop any product candidate, including our lead clinical product candidate, PALI-2108.
  • We depend on our license agreement with Giiant to permit us to use patents and patent applications relating to PALI-2108. Termination of these rights or the failure to comply with our obligations under the license agreement could materially harm our business and prevent us from developing or commercializing PALI-2108, our lead clinical product candidate.
  • Clinical drug development is expensive, time-consuming and uncertain.
  • We are currently conducting a Phase 1 clinical trial of PALI-2108 in Canada, and the FDA or applicable foreign regulatory authorities may not accept data from such trials, or any other trial we conduct outside of the U.S.
  • We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.
  • We expect that our operations and development of PALI-2108 will require more capital than we currently have, and we cannot guarantee when or if we will be able to secure such additional funding.
  • Our product candidates, including our lead clinical product candidate, PALI-2108, may cause undesirable side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.
  • There can be no assurance that our product candidates will obtain regulatory approval.
  • If clinical studies of PALI-2108 do not yield successful results, we may discontinue the development of PALI-2108.
  • It may take us longer than we estimate to complete clinical trials, and we may not be able to complete them at all.
The other 41 risks
  • Even if PALI-2108 is approved for commercialization, future regulatory reviews or inspections may result in its suspension or withdrawal, closure of a facility or substantial fines.
  • The successful commercialization of PALI-2108, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.
  • We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and we may need to limit our commercialization.
  • Even if a product candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.
  • Risks Related to Healthcare Laws and Other Legal Compliance Matters
  • Recent and future changes in healthcare legislation and regulations may increase the difficulty and cost to obtain marketing approval for a drug candidate, increase the costs to commercialize an approved product, and adversely affect the price set for such product.
  • Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.
  • We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.
  • Risks Related to Our Business
  • We have a limited operating history and have never generated any revenues from product sales.
  • Our business model assumes revenue from, among other activities, marketing or out-licensing the products we develop. PALI-2108 is in the early stages of clinical development and because we have a short development history with PALI-2108, there is a limited amount of information about us upon which you can evaluate our business and prospects.
  • Our success depends on attracting and retaining senior management and scientists with relevant expertise.
  • We may choose to discontinue the development or commercialization any of our product candidates, or may choose not to commercialize product candidates in approved indications, at any time during development or after approval, which could adversely affect us and our operations.
  • Our inability to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our ability to grow our business.
  • Changes in funding for the FDA and, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent these agencies or authorities from performing normal business functions on which the operations of our business may rely, which could negatively impact our business.
  • Risks Related to Our Dependence on Third Parties
  • We currently rely on and we intend to continue relying on third-party CROs and other third parties to conduct and oversee our clinical trials. If these third parties do not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations for, obtain regulatory approval for, or commercialize our product candidates.
  • We depend on two qualified suppliers for the active pharmaceutical ingredient used in the clinical trials of PALI-2108. Insufficient availability of the API or other raw materials necessary to manufacture PALI-2108, or the inability of our suppliers to manufacture and supply our products on commercially reasonable terms, could adversely impact our business, results of operations and financial condition.
  • We expect to rely on collaborations with third parties for the successful development and commercialization of our product candidates.
  • We currently rely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates.
  • Risks Related to Our Financial Operations
  • We have a history of net operating losses, and we expect to continue to incur net operating losses and may never achieve profitability.
  • Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated financial statements.
  • Risks Related to Our Intellectual Property
  • We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important to our business.
  • We may be subject to patent infringement claims, which could result in substantial costs and liabilities, and could prevent us from commercializing our potential products.
  • We may be subject to claims that our officers, directors, employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers.
  • Other Risks Related to Our Securities
  • We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all.
  • Our common stock price may be highly volatile.
  • Our common stock could be delisted from the Nasdaq Stock Market if we are unable to maintain compliance with the Nasdaq Stock Market’s continued listing standards.
  • We take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors.
  • We do not anticipate paying any dividends in the foreseeable future.
  • If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
  • Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.
  • If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
  • Our Board has broad discretion to issue additional securities, which might dilute the net tangible book value per share of our common stock for existing stockholders.
  • General Risk Factors
  • Our business could be adversely affected by the effects of health pandemics or epidemics, such as the COVID-19 pandemic, which could cause significant disruptions in our operations and those of our current or future CMOs, CROs, and other third parties upon whom we rely.
  • Global economic conditions may have an adverse effect on our business.
  • Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • If our information systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
  • Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cybersecurity.

Legal proceedings

From time to time, we may be involved in various lawsuits, legal proceedings or claims that arise in the ordinary course of our business. We do not believe there are any claims or actions pending against the Company through December 31, 2025, which will have, individually or in aggregate, a material adverse effect on our business, liquidity, financial position, or results of operations. Litigation, legal proceedings or claims, however, are subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm our business because of defense and settlement costs, diversion of management resources, and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
    SEC EDGAROther events
  50. 50
    SEC EDGAROther events
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72